17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of 1 of the following hematologic malignancies: * Acute myeloid leukemia or acute lymphoblastic leukemia * Not a candidate for potentially curative therapy * WBC ≤ 10,000/mm\^3 OR WBC ≤ 40,000/mm\^3 that is stable for 5 days (hydroxyurea allowed) * No acute promyelocytic leukemia * Non-Hodgkin's lymphoma (NHL), including 1 of the following subtypes: * Small lymphocytic lymphoma * Marginal zone lymphoma * Lymphoplasmacytic lymphoma * Follicular lymphoma * Mantle cell lymphoma * Diffuse large B-cell lymphoma * Anaplastic large cell lymphoma * Peripheral T-cell lymphoma * Extranodal NK/T cell lymphoma (nasal and nasal type) * Enteropathy-type T-cell lymphoma * Hepatosplenic T-cell lymphoma * Angioimmunoblastic T-cell lymphoma * Subcutaneous panniculitis-like T-cell lymphoma * Chronic lymphocytic leukemia (CLL) * Patients with NHL or CLL must meet the following criteria: * Ineligible for, or refused potentially curative stem cell transplantation * Transformed lymphoma/Richter's transformation, defined as the transformation of low-grade lymphoma, including follicular lymphoma, CLL, or small lymphocytic lymphoma to high-grade lymphoma (i.e., diffuse large cell lymphoma) allowed at time of transformation * Evidence of ≥ 50% bone marrow involvement at the time of enrollment OR tumor tissue accessible for biopsy (for patients enrolled after the maximum tolerated dose \[MTD\] is determined) * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Relapsed or refractory disease * Willing to undergo serial bone marrow biopsy (for patients enrolled after the MTD is determined) * No untreated or active CNS leukemia or lymphoma * Performance status - ECOG 0-2 * At least 12 weeks * Bilirubin ≤ 1.5 mg/dL * AST and ALT ≤ 2.5 times upper limit of normal * Creatinine ≤ 2.0 mg/dL * No uncontrolled cardiac disease * No New York Heart Association class III-IV symptomatic congestive heart failure * No unstable angina pectoris * No serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation \> 3 beats in a row) within the past 6 months * No other uncontrolled cardiac arrhythmia or requiring antiarrhythmic drugs * No myocardial infarction within the past year * No active ischemic heart disease within the past year * No congenital long QT syndrome * No left bundle branch block * QTc ≥ 450 msec (for men) or 470 (for women) on ECG/EKG * No history of LVEF \< 50% by MUGA or echocardiogram * Resting ejection fraction ≥ 50% by MUGA or echocardiogram * No prior history of cardiac toxicity after receiving anthracycline therapy (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, or mitoxantrone hydrochloride) * No uncontrolled pulmonary disease * No symptomatic pulmonary disease requiring oxygen or medications * DLCO (i.e., oxygen diffusion capacity) ≥ 80% on pulmonary function testing * Resting and exercise oxygen saturation ≥ 90% by pulse oximetry * No ongoing pulmonary symptoms ≥ grade 2 including any of the following: * Dyspnea on or off exertion * Paroxysmal nocturnal dyspnea * Significant pulmonary disease including chronic obstructive or restrictive pulmonary disease * No prior history of pulmonary toxicity after bleomycin or carmustine * No Medicare requirement for home oxygen (e.g., Resting O\_2 saturation ≥ 90% or desaturation to ≥ 90% with exertion) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No preexisting sensory or motor peripheral neuropathy ≥ grade 2 * No history of allergic reaction to eggs * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No other uncontrolled illness * Prior stem cell transplantation for relapsed or refractory disease allowed * At least 2 weeks since prior immunotherapy and recovered * At least 2 weeks since prior chemotherapy (excluding hydroxyurea) and recovered * No other concurrent chemotherapy * No concurrent routine corticosteroids except for treatment of other medical problems (e.g., pulmonary, rheumatologic, or adrenal disorders) * At least 2 weeks since prior radiotherapy and recovered * No prior radiotherapy that potentially included the heart in the field (e.g., mantle) * No prior history of chest radiation * No concurrent palliative radiotherapy * At least 2 weeks since prior investigational therapy * Prior bortezomib allowed * No other concurrent commercial or investigational agents or therapies for the malignancy